Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Core Insights - Aprea Therapeutics is experiencing strong momentum entering 2026, driven by significant progress in its clinical trials, particularly the ACESOT trial for APR-1051, which has shown early proof of clinical concept with two patients achieving unconfirmed partial responses [2][5] - The company has successfully strengthened its financial position through private placements, enhancing its ability to meet key development milestones [2][10] - Aprea's focus remains on developing targeted therapies for biomarker-defined cancers, with a commitment to improving patient outcomes and shareholder value [2][11] Business Updates - The ACESOT-1051 trial is a Phase 1 study evaluating APR-1051, a WEE1 kinase inhibitor, which has shown promising results in endometrial cancer patients with PPP2R1A mutations [3][5] - The company has appointed Eugene Kennedy, MD, as Chief Medical Advisor to support the next phase of clinical development [5][10] - APR-1051 has demonstrated safety and tolerability, with ongoing dose escalation and plans to enroll additional patients with relevant genomic alterations [6][10] Financial Results - For Q4 2025, Aprea reported an operating loss of $2.6 million, an improvement from a loss of $3.2 million in Q4 2024 [10][19] - Research and Development (R&D) expenses decreased to $1.0 million in Q4 2025 from $2.4 million in Q4 2024, primarily due to lower costs associated with clinical trials [10][19] - The company reported a net loss of $2.5 million ($0.32 per share) for Q4 2025, compared to a net loss of $2.9 million ($0.49 per share) in the same period of 2024 [10][19] Year-End Financial Overview - For the year ended December 31, 2025, Aprea reported an operating loss of $13.2 million, compared to a loss of $14.3 million in 2024 [10][14] - Grant revenues for 2025 were $0.3 million, down from $1.5 million in 2024 [10][14] - As of December 31, 2025, the company had cash and cash equivalents of $14.6 million, down from $22.8 million in 2024, but believes it has sufficient funds to meet projected operating expenses into Q1 2027 [10][17]